Compounds as PDE IV and TNF-inhibitors

Abstract

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

1 - 38 . (canceled)  
     
     
         39 . A compound of formula I  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is lower alkyl optionally substituted by one or more of halo, cycloalkyl or cycloalkenyl;  
 R 2  is alkyl, alkenyl or alkynyl each optionally substituted by one or more of halo, cycloalkyl or cycloalkenyl; or cycloalkyl or cycloalkenyl each optionally substituted by one or more of halo, methylidene or alkyl; or optionally substituted cyclothioalkyl consisting of a non-aromatic monocyclic or multicyclic ring system of 3 to about 10 ring atoms wherein at least one of the ring atoms is sulphur and the other ring atoms are carbon and the substituted cyclothioalkyl is substituted by one or more halo, or any ring sulphur atom is optionally oxidized to the corresponding S-oxide or S,S-dioxide; or optionally substituted cyclothioalkenyl consisting of a non-aromatic monocyclic or multicyclic ring system of 3 to about 10 ring atoms wherein at least one of the ring atoms is sulphur, the other ring atoms are carbon and the ring system contains a carbon-carbon double bond and the substituted cyclothioalkenyl is substituted by one or more halo or any ring sulphur atoms is optionally oxidized to the corresponding S-oxide or S,S-dioxide;  
 R 3  is optionally substituted aryl or heteroaryl, wherein the substituted aryl or substituted heteroaryl group is substituted by one or more substituents which may be the same or different and are selected from alkyl, aryl, aralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkyloxy, carboxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarboxyl, aryloxycarbonyl, aralkyloxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, alkylthio, arylthio, aralkylthio, Y 1 Y 2 N—, Y 1 Y 2  NCO— or Y 1 Y 2  NSO 2 —, where Y 1  and Y 2  are independently hydrogen, alkyl, aryl, and aralkyl;  
 Q 1 , Q 2  and Q 3  are independently nitrogen or CH, provided that at least one of Q 1 , Q 2  and Q 3  is other than CH;  
 Z, Z 1  and Z 2  are independently oxygen or sulfur;  
 Z 3  is —CH═CH—, —CZCH 2 —, —CZ-CZ-, —CH 2 —NH—, —CH 2 —O—, —CX 2 —O—, —CH 2 —S—, —CH 2 —SO 2 — or —CZNH—; and  
 X is halo;  
 or an N-oxide thereof or a pharmaceutically acceptable salt thereof; with the proviso that R 1 Z 1  and R 2 Z 2  cannot both represent methoxy.  
 
     
     
         40 . The compound according to  claim 39  wherein 
 R 2  is alkyl optionally substituted by one or more halo, cycloalkyl or cycloalkenyl; cycloalkyl or cycloalkenyl each optionally substituted by one or more of halo, methylidene or alkyl; or optionally substituted cyclothioalkyl consisting of a non-aromatic monocyclic or multicyclic ring system of 3 to about 10 ring atoms wherein at least one of the ring atoms is sulphur and the other ring atoms are carbon and the substituted cyclothioalkyl is substituted by one or more halo, or any ring sulphur atom is optionally oxidized to the corresponding S-oxide or S,S-dioxide;    R 3  is phenyl, substituted phenyl or azaheteroaryl;    Q 1  and Q 2  are independently nitrogen or CH, provided that at least one of Q 1  and Q 2  is other than CH;    Q 3  is CH; and    Z 3  is —CZCH 2 — or —CZNH—.    
     
     
         41 . The compound according to  claim 40  wherein 
 R 1  is methyl or difluoromethyl;    R 2  is isopropyl, cyclopropylmethyl, cyclopentyl, trinorbornyl, trinorbornenyl, tricyclo[2.2.1.0 2.6. ]heptanyl and tetrahydrothiophenyl;    Z 1  is oxygen or sulphur;    Z 2  is oxygen; and    Z 3  is —COCH 2 — or —CONH—.    
     
     
         42 . The compound according to  claim 39  wherein Q 1  and Q 2  are independently nitrogen or CH, and at least one of Q 1  and Q 2  is nitrogen, and Q 3  is CH.  
     
     
         43 . The compound according to  claim 39  wherein Q 1  is N, and Q 2  and Q 3  are CH; Q 2  is N, and Q 1  and Q 3  are CH; or Q 1  and Q 2  are N, and Q 3  is CH.  
     
     
         44 . The compound according to  claim 39  wherein independently Q 1 , Q 2  or Q 3  is N-oxide or R 3  is azaheterocyclyl having an imine moiety thereof as an N-oxide.  
     
     
         45 . The compound according to  claim 39  wherein Q 1  and Q 3  are CH, and Q 2  is an N-oxide.  
     
     
         46 . The compound according to  claim 39  wherein R 3  is phenyl substituted on the 2-position or on both the 2- and 6-positions.  
     
     
         47 . The compound according to  claim 39  wherein R 3  is heteroaryl substituted on one or both of the positions adjacent to the position of R 3  that is attached to Z 3 .  
     
     
         48 . The compound according to  claim 39  wherein R 3  is azaheteroaryl substituted on one or both of the positions adjacent to a position of R 3  that is attached to Z 3 .  
     
     
         49 . The compound according to  claim 48  wherein R 3  is a 3,5-dihalo-pyrid-4-yl.  
     
     
         50 . The compound according to  claim 49  wherein R 3  is 3,5-dihalo-1-oxido-4-pyridinium.  
     
     
         51 . The compound according to  claim 39  wherein Z 2  is —CZNH— or —CZCH 2 —.  
     
     
         52 . The compound according to  claim 51  wherein Z is oxygen.  
     
     
         53 . The compound according to  claim 39  wherein Z 1  and Z 2  are oxygen, or Z 1  is sulfur and Z 2  is oxygen.  
     
     
         54 . The compound according to  claim 53  wherein Z 1  and Z 2  are oxygen.  
     
     
         55 . The compound according to  claim 39  wherein Z 1  is oxygen.  
     
     
         56 . The compound according to  claim 39  wherein R 1  is lower alkyl optionally substituted by one or more halo.  
     
     
         57 . The compound according to  claim 56  wherein the substitution is on a position of R 1  that is attached to Z 1 .  
     
     
         58 . The compound according to  claim 39  wherein R 2  is lower alkyl, cycloalkyl or cyclothioalkyl optionally substituted by one or more halo.  
     
     
         59 . The compound according to  claim 58  wherein the substitutition is on a position of R 2  that is attached to Z 1 .  
     
     
         60 . The compound according to  claim 58  wherein R 2  is cyclothioalkyl substituted on a position of R 2  that is attached to Z 1  or on a position adjacent to the thio moiety of the cyclothioalkyl.  
     
     
         61 . The compound according to  claim 39  wherein R 2  is isopropyl, cyclopropylmethyl, cyclopentyl, trinorbornyl, trinorbornenyl, tricyclo[2.2.1.0 2.6. ]heptanyl and tetrahydrothiophenyl.  
     
     
         62 . The compound according to  claim 39  wherein R 2  is cyclothioalkyl oxidized to the corresponding S-oxide or S,S-dioxide.  
     
     
         63 . The compound according to  claim 39  wherein R 1  is lower alkyl optionally substituted by halo; and R 2  is isopropyl, cyclopropylmethyl, cyclopentyl, trinorbornyl, trinorbornenyl, tricyclo[2.2.1.0 2.6. ]heptanyl and tetrahydrothiophenyl.  
     
     
         64 . The compound according to  claim 39  which is: 
 5-cyclopentyloxy-N-(3,5-dichloropyrid-4-yl)-6-methoxynicotinamide;    N-(2,6-dichlorophenyl)-5-cyclopentyloxy-6-methoxynicotinamide;    5-cyclopentyloxy-N-(3,5-dimethylisoxazol-4-yl)-6-methoxynicotinamide    5-cyclopentyloxy-N-(3,5-difluoropyrid-4-yl)-6-methoxynicotinamide    6-cyclopentyloxy-N-(3,5-dichloropyrid-4-yl)-5-methoxypyridine-2-carboxamide;    1-(5-cyclopentyloxy-6-methoxypyridin-3-yl)-2-(3,5-dichloropyrid-4-yl)ethanone;    5-cyclopentyloxy-N-(3,5-dichloro-4-pyridyl)-6-methylthionicotinamide;    N-(3,5-dichloro-4-pyridyl)-5-isopropyloxy-6-methylthionicotinamide;    2-(3,5-dichloro-4-pyridyl)-1-(5-isopropyloxy-6-methylthio-3-pyridyl)ethanone;    1-(5-cyclopentyloxy-6-methoxypyrid-3-yl)-2-(3,5-dichloro-1-oxido-4-pyridinio)ethanone hemihydrate;    (±)-N-(3,5-dichloropyrid-4-yl)-6-methoxy-5-exo-(8,9,10-trinorborn-5-en-2-yloxy)nicotinamide;    (±)-N-(3,5-dichloropyrid-4-yl)-6-methoxy-5-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)nicotinamide monohydrate;    N-(3,5-dichloropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-difluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-chloro-6-fluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-trifluoromethylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,4,6-trichlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dibromophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-chloro-6-methylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dichlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-fluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-phenyl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-methoxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-chlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-chlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(4-methoxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dimethylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-methylthiophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-bromophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-methoxycarbonylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-aminosulfonylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-benzoylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-cyanophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,5-dichlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-methylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-nitrophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-dimethylaminophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-acetylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2-hydroxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(4-chloropyrid-3-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-pyrid-2-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-pyrazin-2-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-pyrimidin-2-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-methylpyrid-2-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-pyrid-3-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-chloropyrid-2-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-chloropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-pyrid-4-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-dimethylisoxazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-dibromopyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-dimethylpyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dichloro-4-cyanophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dichloro-4-methoxycarbonylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,3,5-trifluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dichloro-4-ethoxycarbonylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dichloro-4-nitrophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-difluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-bromo-5-chloropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,4,6-trifluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dichloro-4-methoxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(4,6-dichloropyrimid-5-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,3,5,6-tetrafluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-dichloro-2,6-difluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(5-cyano-3-methylisothiazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(2,6-dichloro-4-carbamoylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-chloro-2,5,6-trifluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(4-nitrophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3-methyl-5-bromoisothiazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-dimethylisothiazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;    1-(4-cyclopentyloxy-5-methoxypyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;    (±)-N-(3,5-difluoropyrid-4-yl)-6-methoxy-5-exo-(8,9,10-trinorborn-2-yloxy)nicotinamide;    (±)-N-(3,5-dichloropyridin-4-yl)-6-methoxy-5-exo-(8,9,10-trinorborn-2-yloxy)nicotinamide;    (±)-N-(3,5-dichloropyrid-4-yl)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)pyridine-2-carboxamide;    (±)-N-(3,5-difluoropyrid-4-yl)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)pyridine-2-carboxamide hydrate;    (±)-N-(3,5-dichloropyridin-4-yl)-5-methoxy-4-(tetrahydrothiophen-3-yloxy)pyridine-2-carboxamide;    N-(3,5-dichloropyridin-4-yl)-4-cyclopropylmethoxy-5-methoxypyridine-2-carboxamide;    N-(3,5)dichloropyridin-4-yl)-4-isopropyloxy-5-methoxypyridine-2-carboxamide;    (±)-N-(3,5-dichloro-1-oxido-4-pyridinio)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]-hept-2-yloxy)pyridine-2-carboxamide;    (±)-N-(3,5-difluoro-1-oxido-4-pyridinio)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]-hept-2-yloxy)pyridine-2-carboxamide;    N-(3,5-dichloro-1-oxido-4-pyridinio)-4-isopropyloxy-5-methoxypyridine-2-carboxamide;    N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopropylmethoxy-5-methoxypyridine-2-carboxamide hemihydrate;    (±)-N-(3,5-dichloro-1-oxido-4-pyridinio)-5-methoxy-4-(tetrahydrothiophen-3-yloxy)pyridine-2-carboxamide;    N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopentyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide;    N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopropylmethoxy-5-methoxy-1-oxidopyridinium-2-carboxamide;    N-(3,5-dichloro-1-oxido-4-pyridinio)-4-isopropyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide;    1-(5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)pyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;    (±)-1-(5-methoxy-4-(tetrahydrothiophen-3-yloxy)pyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;    1-(4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)-5-methoxypyridin-2-yl)-2-(3,5-dichloro-1-oxido-4-pyridinio)ethanone;    N-(3,5-dichloropyridin-4-yl)-4-cyclopropylmethoxy-5-methoxy-1-oxidopyridinium-2-carboxamide;    N-(3,5-dichloropyridin-4-yl)-4-isopropyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide;    N-(3,5-dichloropyridin-4-yl)-4-cyclopentyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide hemihydrate;    N-(2-chlorophenyl)-4-cyclopentyloxy-5-methoxy-2-aminomethylpyridine;    trans-2-(2,6-dichlorophenyl)-1-(4-cyclopentyloxy-5-methoxypyrid-2-yl)ethene;    trans-1-(4-cyclopentyloxy-5-methoxypyrid-2-yl)-2-(2,6-difluorophenyl)ethene;    1-(4-cyclopentyloxy-5-methoxypyrid-2-yl)-2-(pyrid-4-yl)ethane-1,2-dione;    N-(3,5-dichloropyrid-4-yl)-5-cyclopentyloxy-6-methoxypyridazine-3-carboxamide;    N-(3,5-dichloropyridin-4-yl)-4-cyclopentyloxy-5-difluoromethoxypyridine-2-carboxamide;    N-(3,5-dichloro-1′-oxido-4-pyridinio)-4-cyclopentyloxy-5-difluoromethoxypyridine-2-carboxamide;    N-(3,5-dichloropyrid-4-yl)-4-cyclopentyloxy-5-difluoromethoxy-1-oxidopyridium-2-carboxamide;    N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopentyloxy-5-difluoromethoxy-1-oxidopyridium-2-carboxamide;    1-(5-difluoromethoxy-4-(cyclopentyloxy)pyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;    1-(5-difluoromethoxy-4-(cyclopentyloxy)-1-oxido-2-pyridium)-2-(3,5-dichloropyridin-4-yl)ethanone;    1-(5-difluoromethoxy-4-(cyclopentyloxy)pyridin-2-yl)-2-(3,5-dichloro-1-oxido-4-pyridinio)ethanone;    1-(5-difluoromethoxy-4-(cyclopentyloxy)-1-oxido-2-pyridium)-2-(3,5-dichloro-1-oxido-4-pyridinio)ethanone;    N-(3,5-dichloropyrid-4-yl)-5,6-dimethoxypyridazine-3-carboxamide; and    1-(5,6-dimethoxypyridazine-3-yl)-2-(3,5-dichloropyridin-4-yl)ethanone.    
     
     
         65 . A pharmaceutical composition comprising a pharmaceutically acceptable amount of the compound of  claim 39  and a pharmaceutically acceptable carrier.  
     
     
         66 . A method for treating a disease state capable of being modulated by inhibiting TNF comprising administering to a patient suffering from said disease state an effective amount of the compound of  claim 39 .  
     
     
         67 . The method of  claim 66  wherein the disease state is an inflammatory disease or autoimmune disease.  
     
     
         68 . The method of  claim 66  wherein the disease state is selected from the group consisting of joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis and osteoarthritis, sepsis, septic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, asthma, bone resorption diseases, reperfusion injury, graft vs host reaction, allograft rejection, malaria, myalgias, HIV, AIDS, cachexia, Crohn's disease, ulcerative colitis, pyresis, systemic lupus erythematosus, multiple sclerosis, type I diabetes mellitus, psoriasis, Beçhet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease and leukemia.  
     
     
         69 . The method of  claim 66  wherein the disease state is joint inflammation.  
     
     
         70 . A method for treating a disease state capable of being modulated by inhibiting production of cyclic AMP phosphodiesterase comprising administering to a patient suffering from said disease state an effective amount of the compound of  claim 39 .  
     
     
         71 . The method of  claim 70  wherein the disease state is a pathological condition associated with a function of cyclic AMP phophodiesterase, eosinophil accumulation or a function of the eosinophil.  
     
     
         72 . The method of  claim 71  wherein the pathological condition is asthma, atopic dermatitis, urticaria, allergic rhinitis, psoriasis, rheumatic arthritis, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome, diabetes insipidus, keratosis, dermatitis, cerebral senility, multi-infarct dementia, senile dementia, memory impairment associated with Parkinson's disease, cardiac arrest, stroke and intermittent claudication.  
     
     
         73 . The method of  claim 71  wherein the pathological condition is asthma.  
     
     
         74 . The compound according to  claim 39  which is  
       
         
           
           
               
               
           
         
       
     
     
         75 . The compound according to  claim 39  wherein Q 2  is N.